17 January 2025 - Telix today announces that it has received a positive decision on the marketing authorisation application for its prostate cancer PET imaging agent Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection), which was submitted in Europe via a decentralised procedure.

This significant milestone follows the issuance of the final assessment report from the German Competent Authority BfArM as reference member state.

Read Telix Pharmaceuticals press release